Kory James Wentworth, CFO of Entrada Therapeutics ($TRDA), sold shares on the open market five times over the past year for a total of $420 thousand. His latest sale occurred on March 10, 2026. These transactions rank 6,838th out of 11,678 insiders in our database, well below the average sale amount of $8.6 million across 6.4 transactions per insider. Wentworth made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | S | Common Stock | 2500 | $12.95 | 119,010.0000 | 41,462,567 | 2.06% | 0.01% |
| March 9, 2026 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | S | Common Stock | 5089 | $13.00 | 132,898.0000 | 41,462,567 | 3.69% | 0.01% |
| March 10, 2026 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | S | Common Stock | 11388 | $13.02 | 121,510.0000 | 41,462,567 | 8.57% | 0.03% |
| March 4, 2026 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | S | Common Stock | 7988 | $12.25 | 137,987.0000 | 41,462,567 | 5.47% | 0.02% |
| March 1, 2026 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | A | Common Stock | 44600 | $0.00 | 154,626.0000 | 41,462,567 | 40.54% | 0.11% |
| March 3, 2026 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | F | Common Stock | 5712 | $11.76 | 145,975.0000 | 41,462,567 | 3.77% | 0.01% |
| March 2, 2026 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | F | Common Stock | 2939 | $11.66 | 151,687.0000 | 41,462,567 | 1.90% | 0.01% |
| March 1, 2026 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | A | Stock Option (Right to Buy) | 66600 | $0.00 | 66,600.0000 | 41,462,567 | 9999.99% | 0.16% |
| Nov. 21, 2025 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | S | Common Stock | 8910 | $9.98 | 110,026.0000 | 41,462,567 | 7.49% | 0.02% |
| Sept. 2, 2025 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | F | Common Stock | 1734 | $5.43 | 118,936.0000 | 39,003,169 | 1.44% | 0.00% |
| April 3, 2025 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | M | Common Stock | 11134 | $2.10 | 120,670.0000 | 39,003,169 | 10.16% | 0.03% |
| April 3, 2025 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | M | Stock Option (Right to Buy) | 11134 | $0.00 | 20,023.0000 | 39,003,169 | 35.74% | 0.03% |
| March 17, 2025 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | S | Common Stock | 1784 | $10.67 | 109,536.0000 | 39,003,169 | 1.60% | 0.00% |
| March 1, 2025 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | A | Stock Option (Right to Buy) | 63300 | $0.00 | 63,300.0000 | 39,003,169 | 9999.99% | 0.16% |
| March 1, 2025 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | A | Common Stock | 42400 | $0.00 | 116,249.0000 | 39,003,169 | 57.41% | 0.11% |
| March 3, 2025 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | F | Common Stock | 4929 | $11.68 | 111,320.0000 | 39,003,169 | 4.24% | 0.01% |
| Nov. 29, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | S | Common Stock | 1000 | $19.97 | 73,849.0000 | 40,629,602 | 1.34% | 0.00% |
| Dec. 2, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | S | Common Stock | 5000 | $20.00 | 73,849.0000 | 40,629,602 | 6.34% | 0.01% |
| Dec. 2, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | M | Common Stock | 5000 | $2.10 | 78,849.0000 | 40,629,602 | 6.77% | 0.01% |
| Nov. 29, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | M | Stock Option (Right to Buy) | 1000 | $0.00 | 36,157.0000 | 40,629,602 | 2.69% | 0.00% |
| Dec. 2, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | M | Stock Option (Right to Buy) | 5000 | $0.00 | 31,157.0000 | 40,629,602 | 13.83% | 0.01% |
| Nov. 29, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | M | Common Stock | 1000 | $2.10 | 74,849.0000 | 40,629,602 | 1.35% | 0.00% |
| Nov. 11, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | M | Common Stock | 6000 | $2.10 | 82,486.0000 | 40,629,602 | 7.84% | 0.01% |
| Nov. 11, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | S | Common Stock | 8637 | $19.98 | 73,849.0000 | 40,629,602 | 10.47% | 0.02% |
| Nov. 11, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | M | Stock Option (Right to Buy) | 6000 | $0.00 | 37,157.0000 | 40,629,602 | 13.90% | 0.01% |
| Sept. 9, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | S | Common Stock | 3195 | $14.97 | 76,486.0000 | 33,050,319 | 4.01% | 0.01% |
| Sept. 3, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | F | Common Stock | 462 | $15.76 | 80,950.0000 | 33,050,319 | 0.57% | 0.00% |
| Sept. 5, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | F | Common Stock | 165 | $15.13 | 79,681.0000 | 33,050,319 | 0.21% | 0.00% |
| Sept. 3, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | F | Common Stock | 14 | $17.70 | 80,787.0000 | 33,050,319 | 0.02% | 0.00% |
| Sept. 4, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | F | Common Stock | 941 | $15.42 | 79,846.0000 | 33,050,319 | 1.16% | 0.00% |
| Sept. 3, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | F | Common Stock | 149 | $16.93 | 80,801.0000 | 33,050,319 | 0.18% | 0.00% |
| July 8, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | S | Common Stock | 1758 | $14.95 | 81,412.0000 | 33,050,319 | 2.11% | 0.01% |
| March 15, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | M | Common Stock | 9000 | $2.10 | 83,170.0000 | 33,050,319 | 12.13% | 0.03% |
| March 15, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | M | Stock Option (Right to Buy) | 9000 | $0.00 | 43,157.0000 | 33,050,319 | 17.26% | 0.03% |
| March 6, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | S | Common Stock | 4086 | $12.31 | 74,170.0000 | 33,050,319 | 5.22% | 0.01% |
| March 1, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | A | Common Stock | 30900 | $0.00 | 80,471.0000 | 33,050,319 | 62.33% | 0.09% |
| March 1, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | A | Stock Option (Right to Buy) | 46800 | $0.00 | 46,800.0000 | 33,050,319 | 9999.99% | 0.14% |
| March 5, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | F | Common Stock | 1471 | $12.28 | 78,256.0000 | 33,050,319 | 1.85% | 0.00% |
| March 4, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | F | Common Stock | 405 | $13.37 | 79,727.0000 | 33,050,319 | 0.51% | 0.00% |
| March 4, 2024 | Entrada Therapeutics, Inc. | $TRDA | WENTWORTH KORY JAMES | Chief Financial Officer | F | Common Stock | 339 | $12.42 | 80,132.0000 | 33,050,319 | 0.42% | 0.00% |